APA

Rubenstein E. B., Gralla R. J., Hainsworth J. D., Hesketh P. J., Grote T. H., Modiano M. R., Khojasteh A., Kalman L. A., Benedict C. R. & Hahne W. F. (19970415). Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. : Cancer.

Chicago

Rubenstein E B, Gralla R J, Hainsworth J D, Hesketh P J, Grote T H, Modiano M R, Khojasteh A, Kalman L A, Benedict C R and Hahne W F. 19970415. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. : Cancer.

Harvard

Rubenstein E. B., Gralla R. J., Hainsworth J. D., Hesketh P. J., Grote T. H., Modiano M. R., Khojasteh A., Kalman L. A., Benedict C. R. and Hahne W. F. (19970415). Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. : Cancer.

MLA

Rubenstein E B, Gralla R J, Hainsworth J D, Hesketh P J, Grote T H, Modiano M R, Khojasteh A, Kalman L A, Benedict C R and Hahne W F. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. : Cancer. 19970415.